(Q412920)

English

daclizumab

pharmaceutical drug

Anti-IL-2
Humanized antiCD25
Ig gamma-1 chain C region
Ro-24-7375
Zinbryta

In more languages

Statements

type of chemical entity

0 references

chemical compound

0 references

1 reference

Daclizumab (English)

language of work or name

publication date

17 November 2015

defined daily dose

0.35 gram

route of administration

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=L04AC01

active ingredient in

1 reference

European Medicines Agency product number

EMEA/H/C/000198

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000198/human_med_001175.jsp

22 March 2017

1 reference

European Medicines Agency product number

EMEA/H/C/003862

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003862/human_med_001987.jsp

22 March 2017

World Health Organisation international non-proprietary name

daclizumab (English)

1 reference

language of work or name

Daclizumab (English)

19 January 2016

medical condition treated

graft-versus-host disease

1 reference

language of work or name

13 December 2016

relapsing-remitting multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

pregnancy category

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category C

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Daclizumab

10 November 2017

has characteristic

biopharmaceutical

1 reference

Daclizumab (English)

language of work or name

publication date

17 November 2015

subject has role

immunosuppressive drug

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

monoclonal antibody

1 reference

language of work or name

Daclizumab (English)

publication date

17 November 2015

0 references

Identifiers

Bibliothèque nationale de France ID

1 reference

30 March 2018

1 reference

30 March 2018

CAS Registry Number

1 reference

language of work or name

Daclizumab (English)

publication date

17 November 2015

1 reference

language of work or name

Daclizumab (English)

19 January 2016

0 references

0 references

1 reference

language of work or name

Daclizumab (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

0 references

MeSH descriptor ID

subject named as

Daclizumab

0 references

D12.776.124.486.485.114.224.060.766

0 references

D12.776.124.790.651.114.224.060.766

0 references

D12.776.377.715.548.114.224.200.766

0 references

1 reference

26 February 2018

2 references

language of work or name

Daclizumab (English)

publication date

17 November 2015

https://www.drugbank.ca/releases/latest#open-data

April 2018

1 reference

language of work or name

DACLIZUMAB (English)

19 January 2016

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

language of work or name

DACLIZUMAB (English)

19 January 2016

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Microsoft Academic ID

0 references

NCI Dictionary of Cancer Terms entry

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

0 references

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(15 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q412920&oldid=2132480766"